10 likes | 156 Views
Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease. LV: -14 g with spironolactone vs. 3 g with placebo (p < 0.01) PW velocity: -0.8 m/s vs. -0.1 m/s (p < 0.01) Systolic blood pressure: -11 mm Hg vs. -5 mm Hg (p < 0.05).
E N D
Effect of Spironolactone on LV Hypertrophy in Chronic Renal Disease LV: -14 g with spironolactone vs. 3 g with placebo (p < 0.01) PW velocity: -0.8 m/s vs. -0.1 m/s (p < 0.01) Systolic blood pressure: -11 mm Hg vs. -5 mm Hg (p < 0.05) Trial design: After a 4-week run-in phase, patients with chronic renal disease were randomized to spironolactone (n = 56) versus placebo (n = 56) for 36 weeks. Results (p < 0.01) (p < 0.01) 3 -0.1 g m/sec Conclusions • Among patients with stage 2 or 3 chronic renal disease, the addition of spironolactone to ACE-I or ARB is beneficial • At 40 weeks, this therapy reduced LV mass, improved arterial stiffness, and reduced blood pressure -0.8 -14 Change in LV mass Change in PW velocity Spironolactone Placebo Edwards NC, et al. J Am Coll Cardiol 2009;54:505-12